A recent study from Johns Hopkins University reveals that isoflavones derived from legumes can significantly reduce inflammation in patients with Chronic Obstructive Pulmonary Disease (COPD). This highlights the increasing importance of nutrition in the management of COPD.
Study Findings
The research led by Belz et al. focused on 99 former smokers diagnosed with COPD. On average, the participants were 66.4 years old and exhibited moderate lung function impairment, with a forced expiratory volume (FEV1) of 49.8 percent.
The study found that an increase in isoflavone intake by one standard deviation resulted in a 7.4 percent decrease in the urinary inflammation marker 11-Dehydro-Thromboxan B2. Isoflavones are particularly abundant in soy products and other legumes. These findings were published in the journal Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.
Improving Symptoms, Not Lung Function
Chronic inflammation in the body can affect not only lung health but also lead to persistent fatigue and joint pain. Patients reported noticeable improvements in their symptoms, with higher isoflavone levels correlating with better scores on the COPD Assessment Test (CAT) and the Clinical COPD Questionnaire (CCQ). Specifically, improvements were evident in coughing scores and mucus expectoration.
However, the researchers found no significant effects on overall lung function or the frequency of exacerbations. Experts warn against uncontrolled supplementation, emphasizing that the beneficial effects were observed only with natural dietary sources.
New Treatments for Asthma and Pulmonary Fibrosis
In addition to nutritional research, significant advancements are being made in medication development. A team from the University of Bonn and the Borstel Research Center discovered a new mechanism to combat allergic asthma. The synthetic peptide Pep19-2.5 (Aspidasept) inhibits the NLRP3 inflammasome, reducing excessive inflammation and improving lung function in laboratory and mouse models.
Further hope arises for patients with pulmonary fibrosis; the EU Commission has approved Nerandomilast (Jascayd), an oral PDE4B inhibitor from Boehringer Ingelheim. This drug aims to slow the decline of lung function in idiopathic pulmonary fibrosis (IPF) and represents the first new therapy option in Europe in over a decade.
Understanding Systemic Inflammation
Many individuals may not realize that joint pain, blood sugar spikes, and chronic exhaustion are often interconnected with inflammatory processes in the body. Learning to combat silent inflammation through diet can be pivotal. There are various natural anti-inflammatory foods that can be easily incorporated into daily eating habits to improve overall well-being.
Researchers at the University of Graz identified long-chain vitamin E metabolites that potentially not only slow chronic inflammation but also promote healing by influencing macrophage activity.
Global Healthcare Disparities
Despite these promising advancements, access to treatments remains uneven around the world. Approximately 750 million individuals deal with chronic lung diseases, with an estimated 3.8 million deaths occurring due to these conditions in 2023 alone. While Brazil has successfully reduced hospital admissions through free inhalers, many regions still lack systematic integration of respiratory therapy into primary care settings.
The economic importance of the sector is underscored by the acquisition of Verona Pharma by Merck for around $100 billion. The reasoning behind this acquisition stems from the successful market introduction of the COPD drug Ensifentrine, which experienced significant sales growth in the first quarter of 2025.
